← Back to patent-cliff list
Debio-4126
Tier C — Watch / tradeDebio-4126
Debiopharm International Sa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SSTR, GHRF
Indications (approved)：Acromegaly, 胃肠胰神经内分泌肿瘤
Regional status
US
Phase III
2025-11-26
EU
Phase III
2025-11-26
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Debio-4126?
Approved indications include: Acromegaly, 胃肠胰神经内分泌肿瘤.
When does the Debio-4126 patent expire?
No public expiry year is available for Debio-4126 yet; this page updates once verified.
How do I get a quote for Debio-4126 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30